1. Home
  2. HDL vs GLUE Comparison

HDL vs GLUE Comparison

Compare HDL & GLUE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

HDL

SUPER HI INTERNATIONAL HOLDING LTD. American Depositary Shares

HOLD

Current Price

$18.32

Market Cap

1.1B

ML Signal

HOLD

Logo Monte Rosa Therapeutics Inc.

GLUE

Monte Rosa Therapeutics Inc.

HOLD

Current Price

$17.41

Market Cap

1.1B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
HDL
GLUE
Founded
2016
2019
Country
Singapore
United States
Employees
N/A
N/A
Industry
Restaurants
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.1B
1.1B
IPO Year
2024
2021

Fundamental Metrics

Financial Performance
Metric
HDL
GLUE
Price
$18.32
$17.41
Analyst Decision
Buy
Analyst Count
0
2
Target Price
N/A
$15.00
AVG Volume (30 Days)
2.0K
925.7K
Earning Date
11-26-2025
11-06-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
0.04
0.25
Revenue
$820,865,000.00
$181,538,000.00
Revenue This Year
$11.19
$81.52
Revenue Next Year
$13.37
N/A
P/E Ratio
$58.13
$68.97
Revenue Growth
8.02
1112.27
52 Week Low
$16.30
$3.50
52 Week High
$30.00
$17.63

Technical Indicators

Market Signals
Indicator
HDL
GLUE
Relative Strength Index (RSI) 54.50 73.73
Support Level $17.66 $15.21
Resistance Level $17.77 $17.63
Average True Range (ATR) 0.31 0.99
MACD 0.13 0.09
Stochastic Oscillator 99.34 95.42

Price Performance

Historical Comparison
HDL
GLUE

About HDL SUPER HI INTERNATIONAL HOLDING LTD. American Depositary Shares

Super Hi International Holding Ltd is an investment holding company and its subsidiaries are principally engaged in restaurant operations, delivery business, and sales of hot pot condiment products and food ingredients located in the overseas market outside Mainland China, Hong Kong, Macau, and Taiwan. Its mission is to become a world-wide integrated restaurant group, build the world's Chinese cuisine brand, and promote Chinese culinary heritage world-wide.

About GLUE Monte Rosa Therapeutics Inc.

Monte Rosa Therapeutics Inc is a biotechnology company that specializes in developing molecular glue degraders (MGDs), a class of small molecule drugs that leverage the body's natural protein destruction mechanisms to selectively degrade therapeutically-relevant proteins. Utilizing the QuEEN platform, the company employ artificial intelligence and proprietary experimental tools to identify target proteins for degradation by MGDs. With a diverse library of over 50,000 MGD molecules, their product candidate, MRT-2359, targets the translation termination factor protein GSPT1 for potential use in MYC-driven tumors. The company's focus lies in advancing its pipeline of MGDs, aiming to provide novel therapeutic modalities for various diseases.

Share on Social Networks: